What are the additional risks of prescribing Prolia (denosumab) for a patient with osteopenia?

Prolia (Denosumab) for Osteopenia: Additional Risks

Prolia should not be used for osteopenia—it is indicated only for osteoporosis at high fracture risk, and using it in osteopenia exposes patients to serious risks without established benefit. 1

Why Prolia is Not Appropriate for Osteopenia

The 2019 Endocrine Society guidelines explicitly recommend denosumab only for postmenopausal women with osteoporosis who are at high risk for osteoporotic fractures 1. Osteopenia (low bone mass without osteoporosis) does not meet this threshold. The guidelines emphasize that denosumab should be reserved as an alternative initial treatment specifically for those with established osteoporosis and high fracture risk.

Unique and Serious Risks of Denosumab

Rebound Vertebral Fractures (Most Critical Risk)

Denosumab cannot be stopped without immediate transition to another antiresorptive agent. The guidelines state unequivocally: "administration of denosumab should not be delayed or stopped without subsequent antiresorptive [e.g., bisphosphonates, hormone therapy, or selective estrogen receptor modulators] or other therapy administered to prevent a rebound in bone turnover and to decrease the risk of rapid bone mineral density loss and an increased risk of fracture" 1.

This rebound effect includes:

• Rapid bone loss exceeding baseline levels
• Risk of multiple vertebral fractures approaching 20% in postmenopausal women 2
• Occurs within 6-12 months of discontinuation
• Requires high-dose potent bisphosphonates to mitigate 2

Unlike bisphosphonates, which allow drug holidays, denosumab commits patients to indefinite treatment or complex transition protocols 1. This is particularly problematic in osteopenia where treatment may not be warranted long-term.

Osteonecrosis of the Jaw (ONJ)

The risk of ONJ with denosumab for osteoporosis is 2.3% following dental extractions—7.7 times higher than oral bisphosphonates (0-0.3%) 3. Risk factors include:

• Number of tooth extractions (odds ratio 1.35 per extraction) 3
• Early resumption of denosumab after dental procedures 3
• Baseline dental evaluation and avoidance of invasive dental surgery during therapy are mandatory 4

Infection Risks

Denosumab increases infection risk, particularly in the first 2 years of treatment 5:

• Pneumonia/influenza (aHR 1.33)
• Urinary tract infections (aHR 1.36)
• Tuberculosis (aHR 1.60)
• Fungal infections (aHR 1.67)
• Sepsis (aHR 1.54)
• Herpes zoster (aHR 1.27)
• Increased mortality (aHR 1.26) 5

The infection risk attenuates significantly after 2 years 5, but this early vulnerability is particularly concerning in osteopenia where immediate fracture risk is lower.

Atypical Femoral Fractures (AFF)

While rare, denosumab is associated with AFFs 6, 7. Evidence shows:

• AFFs can occur even during denosumab treatment 7
• Risk may persist or worsen with bilateral recurrent fractures reported 7
• Denosumab should be avoided in patients with prior AFF 7

Severe Hypocalcemia

Denosumab causes hypocalcemia more frequently than bisphosphonates (13% vs 6%) 4. This risk is:

• Particularly severe in renal impairment 4
• Requires calcium and vitamin D supplementation 4
• Mandates serum calcium monitoring 4

Cardiovascular Risks

Recent data suggests denosumab may increase cardiovascular risk in certain populations. In dialysis patients, denosumab was associated with increased major adverse cardiovascular events (HR 1.690) compared to bisphosphonates 8, though this population differs from typical osteopenia patients.

Neuropsychiatric Effects

Case reports and FAERS data indicate potential neuropsychiatric adverse reactions including cognitive impairment, depression, and psychomotor disturbances, particularly in patients with pre-existing neurobiological vulnerability 9. Of denosumab-related adverse events, 5.7% involved psychiatric/neurological disorders 9.

Clinical Algorithm: When Denosumab Might Be Considered (Not for Osteopenia)

Appropriate candidates (per guidelines):

1. Postmenopausal women with osteoporosis (not osteopenia)
2. High fracture risk documented by FRAX or prior fractures
3. Patient can commit to indefinite treatment or planned transition
4. No contraindications: active infections, hypocalcemia, severe renal impairment
5. Adequate dental health with no planned invasive procedures
6. Bisphosphonates inappropriate or not tolerated 1

For osteopenia specifically:

• First-line: Lifestyle modifications, calcium, vitamin D 10, 11
• Pharmacologic treatment generally not indicated unless additional high-risk features present
• If treatment needed: oral bisphosphonates preferred (allow drug holidays, lower ONJ risk) 6

Critical Pitfalls to Avoid

1. Never start denosumab without a clear long-term plan for continuation or transition
2. Never stop denosumab abruptly—requires immediate antiresorptive transition 1
3. Never use in osteopenia—risks outweigh unproven benefits
4. Delay next dose 6-7 months after dental extractions (no ONJ cases in this window) 3
5. Monitor closely for infections in first 2 years 5
6. Ensure adequate calcium/vitamin D and monitor serum calcium 4

The bottom line: Denosumab's unique rebound fracture risk, inability to discontinue safely, higher ONJ risk, and infection concerns make it inappropriate for osteopenia where fracture risk is lower and treatment may not be lifelong.